Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, discusses the issue of patients or payers objecting to repeat biopsies.
[powerpress]
Dr. Greg Riely, from Memorial Sloan-Kettering, discusses the concept of multiplex next generation sequencing and how it could change molecular oncology.
[powerpress]
Dr. Phil Bonomi, from Rush University, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.
[powerpress]
Dr. Karen Kelly of the University of California, Davis, discusses the evidence and her personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.
[powerpress]
Dr. David Spigel addresses the question of whether to obtain molecular marker results in patients with early stage lung cancer and what to do with that information if it is available for potential application in the adjuvant setting.
[powerpress]
Dr. Sarah Goldberg, Yale Cancer Center, reviews her thought process in recommending a repeat biopsy at initial diagnosis or after progression for patients with advanced lung cancer.
[powerpress]
Drs. Ross Camidge and Corey Langer provide their perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.
[powerpress]
Dr. Lecia Sequist of Massachusetts General Hospital gives her view on more widespread availability of new mutation tests.
[powerpress]
Dr. Heather Wakelee from Stanford University offers her insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent for lung cancer.
[powerpress]
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.